Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN).
Intest Res. 2023;21(2):244-251
Inflammatory bowel disease (IBD) is a chronic refractory idiopathic inflammatory disorder of the gastrointestinal tract. The prevalence of ankylosing spondylitis (AS), a rare type of arthritis, is higher in IBD patients compared to that of the general population. What is the relationship between IBD and AS? Is the concomitant AS associated with the poor clinical outcomes?
In the present study, 55 IBD patients were diagnosed as having AS among 4,722 IBD patients from 2004 to 2021 (IBD-AS group). The proportion of biologics or small molecules was higher in IBD-AS group (27.3%) compared to IBD only group (12.7%) (P = 0.036). There were no significant differences in bowel resection rate, emergency room visit frequency, and underlying diseases between both groups. In the subgroup analysis, the proportion of biologics or small molecules was still higher in ulcerative colitis (UC)-AS group compared to UC only group, but there were no differences in Crohn’s disease (CD)-AS group compared to CD only group.
 - Among 4,722 IBD patients, 55 patients were diagnosed as having AS in three tertiary hospitals in South Korea.
- In this study, IBD-AS group is associated with a higher possibility of biologics or small molecule use compared to AS only group.
|
Read more about the clinical outcomes in IBD-AS patients compared to IBD only patients.
Best regards, |
